Explore the vast range of titles available.

•Sativex® trial patients were drug tested using roadside oral fluid screening devices.•THC is detectable by the Cozart® DDS for at least 2h after dosage.•Confirmatory analysis will reveal elevated CBD levels in Sativex® patients.•Further study is required to exclude concurrent use of non-medicinal cannabis. Sativex® is an oromucosal spray used to treat spasticity in multiple sclerosis sufferers in some European countries, the United Kingdom, Canada and New Zealand. The drug has also recently been registered by the Therapeutic Goods Administration (TGA) in Australia for treatment of multiple sclerosis. Sativex® contains high concentrations of Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), with the former being the subject of random roadside drug tests across Australia to detect cannabis use. This pilot study aims to determine whether or not patients taking Sativex® will test positive to THC using these roadside screening tests. Detectable levels of THC, CBD and cannabinol (CBN) in their oral fluid were also confirmed by liquid chromatography–tandem mass spectrometry (LC–MS/MS). The study was a double-blind, placebo controlled design. Oral fluid was tested prior to and immediately after dosing with either Sativex® or placebo at intervals up to 2h after the dose. Two Sativex® doses were studied. The low dose contained 5.4mg THC, the high dose 21.6mg THC. Results indicate that the primary screening test used in Australian roadside drug testing, the DrugWipe® II Twin, often gave a false negative response for THC, even with high concentrations present. However, secondary screening test, Cozart® DDS (used by police after a DrugWipe test gives a positive result), gave true positive results in all cases where patients were being treated with Sativex®. Confirmatory testing showed high concentrations of THC and CBD (>5356ng/mL THC and >3826ng/mL CBD) in the oral fluid shortly after dosing and also elevated concentrations of CBN. Levels dropped quickly but remained at detectable concentrations (>67.6ng/mL) two hours after drug administration. The average concentration ratio of THC/CBD across all positive samples was 1.10 (%RSD 19.9) reflecting the composition of the Sativex® spray. In conclusion, Sativex® users may test positive for THC by roadside drug testing within 2–3h of use. Confirmatory analysis can identify Sativex® treatment through use of THC/CBD ratios, however, these ratios would unlikely be sufficient to differentiate non-medicinal cannabis use from Sativex® use if both are taken concurrently.

dl-3,4-methylenedioxymethamphetamine (MDMA) and methamphetamine are commonly used illicit drugs that are thought to impair driving ability. The Standardized Field Sobriety Tests (SFSTs) are utilized widely to detect impairment associated with drugs other than alcohol in drivers, although limited evidence concerning MDMA and methamphetamine consumption on SFST performance exists. The aim of this study was to evaluate whether the SFSTs were a sensitive measure for identifying the presence of the specific isomer d-methamphetamine and MDMA. In a double-blind, within-subject, counter-balanced and placebo-controlled study, 58 healthy and abstinent recreational drugs users were administered three treatments: 100mg of MDMA, 0.42mg/kg d-methamphetamine, and placebo. For each condition the SFSTs were administered at 4 and 25h post treatment. d-methamphetamine was not found to significantly impair SFST performance unlike MDMA, which significantly impaired SFST performance in comparison to placebo with 22% of the sample failing the test at the 4h testing time-point. No differences were observed at the 25h testing time-point for any of the conditions. It was concluded that the SFSTs are not efficient in identifying the presence of low level d-methamphetamine, and are significantly better at detecting the presence of MDMA at the levels assessed.

•A simplified clinical test was less sensitive than psychomotor tests in detecting impairment.•A positive clinical test result can still be useful for roadside impairment detection.•It can indicate impairing blood levels of ethanol and zopiclone with high specificity. The risk of traffic accident involvement is increased among patients prescribed the z-hypnotic drug zopiclone. Clinical test observations able to indicate drug impairment are therefore essential. This study compared the findings of a simplified clinical test of impairment (SCTI) with those of a battery of computerized psychomotor tests of impairment (CPTI). 16 healthy young male volunteers attended a research unit on four different study days, receiving in randomized order either placebo, zopiclone 5mg, zopiclone 10mg, or alcohol 50g. The SCTI was performed twice and the CPTI was performed three times on each study day, with blood samples being collected for drug analysis. The SCTI (and the CPTI) was able to demonstrate impairment at 1.5h, but no major impairment was found at 7h with the SCTI, after intake of both zopiclone and ethanol. The CPTI detected a significantly higher proportion of impaired observations than the SCTI, both for zopiclone and for ethanol, at all concentration levels. The sensitivity of the clinical tests in detecting blood drug concentrations often associated with impairment, due to zopiclone (above 23ng/ml) and alcohol (above 0.5g/l), was low, revealing 27 per cent and 18 per cent, respectively. The specificity, however, was higher, both for zopiclone (88 per cent) and for alcohol (96 per cent). The SCTI may be a useful tool, especially during roadside investigation, when the police are in doubt as to whether the apprehended driver is impaired or not. A subject, who has consumed zopiclone or alcohol, tested with the SCTI, with one or more subtests diverging from a habitual result, is likely to have a blood zopiclone concentration above 23ng/ml or a BAC above 0.5g/l. A negative result, however, is less helpful.

The proliferation of new psychoactive substances (NPS) in recent years has resulted in the development of numerous analytical methods for the detection and identification of known and unknown NPS derivatives. High-resolution mass spectrometry (HRMS) has been identified as the method of choice for broad screening of NPS in a wide range of analytical contexts because of its ability to measure accurate masses using data-independent acquisition (DIA) techniques. Additionally, it has shown promise for non-targeted screening strategies that have been developed in order to detect and identify novel analogues without the need for certified reference materials (CRMs) or comprehensive mass spectral libraries. This paper reviews the applications of HRMS for the analysis of NPS in forensic drug chemistry and analytical toxicology. It provides an overview of the sample preparation procedures in addition to data acquisition, instrumental analysis, and data processing techniques. Furthermore, it gives an overview of the current state of non-targeted screening strategies with discussion on future directions and perspectives of this technique. Graphical Abstract Missing the bullseye - a graphical respresentation of non-targeted screening. Image courtesy of Christian Alonzo

Background: Oral fluid (OF) is an exciting alternative matrix for monitoring drugs of abuse in workplace, clinical toxicology, criminal justice, and driving under the influence of drugs (DUID) programs. During the last 5 years, scientific and technological advances in OF collection, point-of-collection testing devices, and screening and confirmation methods were achieved. Guidelines were proposed for workplace OF testing by the Substance Abuse and Mental Health Services Administration, DUID testing by the European Union’s Driving under the Influence of Drugs, Alcohol and Medicines (DRUID) program, and standardization of DUID research. Although OF testing is now commonplace in many monitoring programs, the greatest current limitation is the scarcity of controlled drug administration studies available to guide interpretation. Content: This review outlines OF testing advantages and limitations, and the progress in OF that has occurred during the last 5 years in collection, screening, confirmation, and interpretation of cannabinoids, opioids, amphetamines, cocaine, and benzodiazepines. We examine controlled drug administration studies, immunoassay and chromatographic methods, collection devices, point-of-collection testing device performance, and recent applications of OF testing. Summary: Substance Abuse and Mental Health Services Administration approval of OF testing was delayed because questions about drug OF disposition were not yet resolved, and collection device performance and testing assays required improvement. Here, we document the many advances achieved in the use of OF. Additional research is needed to identify new biomarkers, determine drug detection windows, characterize OF adulteration techniques, and evaluate analyte stability. Nevertheless, there is no doubt that OF offers multiple advantages as an alternative matrix for drug monitoring and has an important role in DUID, treatment, workplace, and criminal justice programs.

The added value of dried blood spot (DBS) samples complementing the information obtained from commonly routine doping control matrices is continuously increasing in sports drug testing. In this project, a robotic-assisted non-destructive hematocrit measurement from dried blood spots by near-infrared spectroscopy followed by a fully automated sample preparation including strong cation exchange solid-phase extraction and evaporation enabled the detection of 46 lower molecular mass (< 2 kDa) peptide and non-peptide drugs and drug candidates by means of LC-HRMS. The target analytes included, amongst others, agonists of the gonadotropin-releasing hormone receptor, the ghrelin receptor, the human growth hormone receptor, and the antidiuretic hormone receptor. Furthermore, several glycine derivatives of growth hormone–releasing peptides (GHRPs), arguably designed to undermine current anti-doping testing approaches, were implemented to the presented detection method. The initial testing assay was validated according to the World Anti-Doping Agency guidelines with estimated LODs between 0.5 and 20 ng/mL. As a proof of concept, authentic post-administration specimens containing GHRP-2 and GHRP-6 were successfully analyzed. Furthermore, DBS obtained from a sampling device operating with microneedles for blood collection from the upper arm were analyzed and the matrix was cross-validated for selected parameters. The introduction of the hematocrit measurement method can be of great value for doping analysis as it allows for quantitative DBS applications by managing the well-recognized “hematocrit effect.”

[Display omitted] The analysis of illicit drugs faces many challenges, mainly regarding the production of timely and reliable results and the production of added value from the generated data. It is essential to rethink the way this analysis is operationalised, in order to cope with the trend toward the decentralization of forensic applications. This paper describes the deployment of an ultra–portable near-infrared detector connected to a mobile application. This allows analysis and display of results to end users within 5s. The development of prediction models and their validation, as well as strategies for deployment within law enforcement organizations and forensic laboratories are discussed.

3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, is a widely abused psychoactive substance, especially in the context of club and party scenes. Due to its prevalence and the associated health risks, rapid and reliable methods for its detection are essential, particularly for forensic investigations. This study presents the development of a portable sensor system for the detection of MDMA using screen-printed carbon electrodes (SPCE) and square wave voltammetry (SWV) technique. The SPEs were manually fabricated in the laboratory, and the electrochemical behavior of MDMA was thoroughly characterized, with special attention given to the influence of pH on the oxidation process. The method was optimized for quantitative analysis with a detection limit of 0.5 µM and a linear range of 2.5–50 µM. The sensor demonstrated high reproducibility, satisfactory precision (intra-day CV%: 2.1–7.1 %; inter-day CV%: 5.4–6.3 %), and excellent recovery rates (89–105 %). The system was successfully applied to the analysis of authentic ecstasy samples, and the results were consistent with those obtained by the reference UHPLC-DAD method. The fully manual fabrication, cost-effectiveness, and low detection limits of this sensor system, combined with its simplicity, portability, and reliability, suggest its strong potential as an effective and accessible tool for on-site MDMA detection in forensic applications, even in resource-limited settings. [Display omitted] •A miniaturized, fully in-laboratory fabricated, low-cost sensor for MDMA detection.•Provides rapid, reliable on-site drug analysis for forensic investigations.•Achieves low LOD, rivaling nanomaterial-modified and commercial electrodes.•Eco-friendly, reagent-minimizing approach for sustainable forensic applications.

Injecting drug use poses significant public health risks due to unsafe practices such as syringe sharing, reuse, and risky sexual behaviors, which increase the transmission of bloodborne viruses. In Tunisia, limited data on injecting drug use hinders the development of informed health and harm reduction policies. A syringe collection campaign was conducted in Tunis in November 2022. The used syringes were provided by the Tunisian Association for Information and Orientation on AIDS and Addiction (ATIOST), a harm-reduction service. These syringes had been distributed to people who inject drugs (PWID) as part of a mobile syringe exchange program. The objective of the study was to analyze the contents of the used syringes to gain further insights into drug use patterns among PWID. The residual substances in the syringes were examined using ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), in accordance with the standardized protocol of the European Syringe Collection and Analysis Project Enterprise (ESCAPE). A total of 261 syringes from five collection sites were analyzed. Among these, 87 % contained at least one psychoactive substance, while 32 % contained more than two psychoactive substances. The most frequently identified psychoactive substances were buprenorphine (50.28 %), amphetamine (11.65 %) and tramadol (9.66 %). No substances were detected in 34 syringes. This method provides rapid data on drug use trends in specific regions and timeframes, revealing differences that can inform tailored prevention and harm reduction strategies. Such analyses are valuable for comparative studies across countries in the European Neighbourhood Policy (ENP-South) region. [Display omitted] •261 syringes analyzed; 87 % contained at least one psychoactive substance.•Buprenorphine (50.28 %) was the most detected, followed by tramadol and amphetamines.•New psychoactive substances like fentanyl and synthetic cathinones were found.•32 % of syringes had multiple substances indicating risky behavior and syringe sharing.•Results guide harm reduction efforts and enhance drug monitoring approaches.

Synthetic cannabinoids are one of the many substances of abuse widely spreading in modern society. Medical practitioners and law enforcement alike highly seek portable, efficient, and reliable tools for on-site detection and diagnostics. Here, we propose a colorimetric lateral flow assay (LFA) combined with dye-loaded polymersome to detect the synthetic cannabinoid JWH-073 efficiently. Rhodamine B–loaded polymersome was conjugated to antibodies and fully characterized. Two LFA were proposed (sandwich and competitive), showing a high level of sensitivity with a limit of detection (LOD) reaching 0.53 and 0.31 ng/mL, respectively. The competitive assay was further analyzed by fluorescence, where the LOD reached 0.16 ng/mL. The application of the LFA over spiked synthetic saliva or real human saliva demonstrated an overall response of 94% for the sandwich assay and 97% for the competitive LFA. The selectivity of the system was assessed in the presence of various interferents. The analytical performance of the LFA system showed a coefficient of variation below 6%. The current LFA system appears as a plausible system for non-invasive detection of substance abuse and shows promise for synthetic cannabinoid on-site sensing. Graphical abstract